Wide Ranks

DRMA

Dermata Therapeutics, Inc.

1.10

Top Statistics
Market Cap 2 M Forward PE -0.2842 Revenue Growth 0.00 %
Current Ratio 2.73 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 4 M Total Cash Per Share 3.76 Total Debt
Total Debt To Equity Current Ratio 2.73 Book Value Per Share 24.25
All Measures
Short Ratio 52.00 % Message Board Id finmb_283634456 Shares Short Prior Month 69108
Return On Equity -1.73 City San Diego Uuid 2eb28598-dc3c-37ac-ae7f-fbf2fb5c41fa
Previous Close 1.12 First Trade Date Epoch Utc 1 B Book Value 24.25
Beta 0.7920 Volume 12196 Price To Book 0.0454
Last Split Date 1 B Fifty Two Week Low 1.05 Total Cash Per Share 3.76
Shares Short Previous Month Date 1 B Target Median Price 6.00 Max Age 86400
Recommendation Mean 2.00 Sand P52 Week Change 0.3133 Target Mean Price 6.00
Net Income To Common -9816552 Short Percent Of Float 0.0628 Implied Shares Outstanding 2 M
Trailing Peg Ratio None Last Fiscal Year End 1 B Average Daily Volume10 Day 93630
Average Volume10days 93630 Total Cash 4 M Next Fiscal Year End 1 B
Held Percent Insiders 0.0084 Trailing PE 0.0000 Date Short Interest 1 B
Most Recent Quarter 1 B Regular Market Previous Close 1.12 Target Low Price 6.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.37 Open 1.17
Free Cashflow -4237496 State CA Dividend Yield 0.00 %
Return On Assets -0.9068 Time Zone Short Name EST Trailing Eps -13.36
Day Low 1.10 Address1 3525 Del Mar Heights Road Shares Outstanding 2 M
Price Hint 4 Target High Price 6.00 Website https://www.dermatarx.com
52 Week Change -0.9016 Average Volume 528879 Forward Eps -3.87
Recommendation Key buy Compensation As Of Epoch Date 1 B Quick Ratio 257.90 %
Last Split Factor 1:15 Regular Market Day High 1.17 Is_sp_500 False
Profit Margins 0.00 % Fifty Two Week High 13.35 Day High 1.17
Shares Short 93737 Regular Market Open 1.17 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.0621
Operating Cashflow -7749340 Currency USD Time Zone Full Name America/New_York
Market Cap 2 M Is_nasdaq_100 False Zip 92130
Quote Type EQUITY Industry Biotechnology Long Name Dermata Therapeutics, Inc.
Regular Market Day Low 1.10 Held Percent Institutions 0.0066 Current Price 1.10
Address2 Suite 332 Financial Currency USD Current Ratio 2.73
Industry Disp Biotechnology Number Of Analyst Opinions 1 Country United States
Float Shares 1 M Two Hundred Day Average 3.28 Enterprise Value -3382398
Forward PE -0.2842 Regular Market Volume 12196 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases.

The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea.

It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions.

Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.